Smartkarma Daily Briefs

• Wash trading was at one point a pervasive problem in cryptocurrency markets.
• Today, most major exchanges have strict anti-wash trading measures, which has drastically reduced the problem since the ICO-led trading boom of 2017-18.
• Yet, due to the relatively low barriers to entry for launching an exchange, this type of market manipulation is far from eradicated on lesser-known, unregulated venues. 

• Bill Ackman’s analysis was good, but his timing was poor. Netflix subscriptions recover, but margins fall.
• The outlook for Netflix under a new leadership model is good, according to Ackman.
• Netflix stock bottomed as expected, but it was down for the first time since Ackman took over.

• Beijing’s city market regulator has warned the public to steer clear of firms promising big returns with little risk from investments in non-fungible tokens (NFTs) and the metaverse.
• The statement is the latest indication that China’s watchdogs are unlikely to change their stance on speculative investments like NFTs, a form of digital token, anytime soon.
• The latest warning comes less than two years after China outlawed cryptocurrency trading and mining, also seeking to stamp out rampant speculative investment in virtual currencies like bitcoin and ether.

• Barrick Gold Corporation’s stock is bearish on the premise of underwhelming operational performance and an overblown gold price outlook.
• However, ramp-ups of critical assets are yet to be realized, according to the company.
• Barrick is committed to a substantial share buyback program and promises solid dividends.

• Record high quarterly margins at Disney’s parks and experiences would not be the silver bullet to high shareholder returns.
• Higher future margins are already priced in and with that upside appears limited, even if management executes on its current strategy.
• Disney’s business model is shaken by yet another restructuring, according to the company.

• Abbvie Inc (ABBV US) reported 4Q22 results, with revenue increasing 2% to $15B, mainly driven by Skyrizi and Rinvoq. EPS grew 17% to $3.60, better than consensus and company guidance.
• The company has initiated 2023 EPS guidance at $10.70–11.10, representing a decline of 19–22% YoY, as Humira has started facing competition in the U.S.
• 2023 guidance contemplates the expected headwind from direct biosimilar competition, with the U.S. Humira sales declining ~37%, which is at the lower end of previous erosion projection of 35–55%.

• LiDAR works by emitting laser beams and measuring the time it takes for the beams to bounce back to the sensor.
• By using this information, LiDAR can create a 3D map of the surrounding environment, including the location and shape of objects, such as buildings, trees, pedestrians, and vehicles.
• One of the main advantages of LiDAR is its accuracy and range.

• On February 9, SES announced it was awarded cash grants from the South Korean Central Government, represented by the Ministry of Trade, Industry and Energy (MOTIE), as well as Chung-Buk Province and Chung-Ju City.
• In September 2022, President Yoon Suk Yeol of the Republic of Korea invited Dr. Qichao Hu, CEO and founder of SES, to a meeting, which included CEOs of renowned US technology firms, to discuss how SES and the South Korean government may collaborate to advance next-generation battery technology.
• Following this meeting, SES announced its intention to increase investments in South Korea to support manufacturing and development of its large-capacity Apollo cells.

Immix Biopharma has announced interim response rate data from its newly formed subsidiary, Nexcella, concerning the BCMA-targeting cell therapy NXC-201 in multiple myeloma and AL amyloidosis. The data, presented at the 5th European CAR T-cell Meeting, shows a 90% overall response rate (ORR) in 29 patients (of 42 total enrolled) treated with NXC-201 at the recommended Phase II dose (RP2D). This result is comparable to approved BCMA-targeting cell therapies. Importantly, cytokine release syndrome was manageable, and no neurotoxicity was observed at the RP2D (800m cells). In our view, NXC-201’s potential main point of differentiation is its favorable safety profile, which we believe the latest data supports. Immix will continue to investigate NXC-201 as the first potential outpatient CAR T-cell therapy. This announcement follows the recent initiation of patient enrolment in a new Phase Ib/IIa clinical trial, investigating the use of Immix’s lead asset, IMX-110, in combination with tislelizumab (BeiGene/Novartis’s anti-PD-1 antibody) for the treatment of advanced solid tumors.